- Conditions
- Leukemia, Myelodysplastic Syndromes
- Interventions
- clofarabine, melphalan, gene expression analysis, reverse transcriptase-polymerase chain reaction, flow cytometry, laboratory biomarker analysis, allogeneic hematopoietic stem cell transplantation
- Drug · Genetic · Other + 1 more
- Lead sponsor
- City of Hope Medical Center
- Other
- Eligibility
- 1 Year to 120 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2011
- U.S. locations
- 1
- States / cities
- Duarte, California
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 2041–2064
of 3,412
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Mandible Tumor, Mandibular Injuries, Mandible; Deformity
- Interventions
- EB-CMF
- Combination Product
- Lead sponsor
- Epibone, Inc.
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 3
- States / cities
- San Francisco, California • Cleveland, Ohio • San Antonio, Texas
- Conditions
- Leukemia
- Interventions
- filgrastim, sargramostim, cyclosporine, cytarabine, daunorubicin hydrochloride
- Biological · Drug
- Lead sponsor
- SWOG Cancer Research Network
- Network
- Eligibility
- 56 Years and older
- Enrollment
- 69 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2010
- U.S. locations
- 97
- States / cities
- Mobile, Alabama • Tucson, Arizona • Orange, California + 62 more
- Conditions
- Myelodysplastic Syndromes, Refractory Anemia With Excess Blasts, Chronic Myelomonocytic Leukemia, Cytopenia
- Interventions
- rigosertib sodium
- Drug
- Lead sponsor
- Traws Pharma, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 67 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2017
- U.S. locations
- 14
- States / cities
- Stanford, California • Chicago, Illinois • Westwood, Kansas + 7 more
- Conditions
- Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia
- Interventions
- Biospecimen Collection, Dual-Energy Computed Tomography, Fluorothymidine F-18, Laboratory Biomarker Analysis, Magnetic Resonance Imaging, Positron Emission Tomography
- Procedure · Drug · Other
- Lead sponsor
- City of Hope Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 82 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2026
- U.S. locations
- 1
- States / cities
- Duarte, California
- Conditions
- Graft Versus Host Disease, Leukemia, Lymphoma
- Interventions
- anti-thymocyte globulin, cyclophosphamide, cyclosporine, methotrexate, methylprednisolone, allogeneic bone marrow transplantation, in vitro-treated bone marrow transplantation, radiation therapy
- Drug · Procedure
- Lead sponsor
- Masonic Cancer Center, University of Minnesota
- Other
- Eligibility
- Up to 45 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1996 – 2000
- U.S. locations
- 1
- States / cities
- Minneapolis, Minnesota
- Conditions
- Graft Vs Host Disease
- Interventions
- Prochymal® - 2 Million cells/kg, Prochymal®- 8 Million cells/kg, Methylprednisolone, Prednisone, Cyclosporine, Tacrolimus, Mycophenolate Mofetil
- Drug
- Lead sponsor
- Mesoblast, Inc.
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 32 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2008
- U.S. locations
- 9
- States / cities
- Indianapolis, Indiana • Kansas City, Missouri • Hackensack, New Jersey + 6 more
- Conditions
- Accelerated Phase Chronic Myelogenous Leukemia (CML), Blast Phase Chronic Myelogenous Leukemia (CML), Chronic Phase Phase Chronic Myelogenous Leukemia (CML), Philadelphia Chromosome Positive (Ph+) Phase Chronic Myelogenous Leukemia (CML)
- Interventions
- Axitinib, Bosutinib, Laboratory Biomarker Analysis
- Drug · Other
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 4 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Basal Cell Nevus Syndrome, Gorlin Syndrome
- Interventions
- GDC-0449
- Drug
- Lead sponsor
- UCSF Benioff Children's Hospital Oakland
- Other
- Eligibility
- 35 Years to 75 Years
- Enrollment
- 41 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2014
- U.S. locations
- 2
- States / cities
- Oakland, California • New York, New York
- Conditions
- Multiple Myeloma
- Interventions
- Radiation
- Radiation
- Lead sponsor
- University of Chicago
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Acute Myeloid Leukemia, Myelodysplastic Syndromes, Myeloid Malignancies, MDS, Inherited Bone Marrow Failure Syndrome, Myeloid Neoplasm, Aml
- Interventions
- Decitabine, Filgrastim
- Drug
- Lead sponsor
- Franziska Wachter
- Other
- Eligibility
- 1 Year to 39 Years
- Enrollment
- 29 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2029
- U.S. locations
- 2
- States / cities
- Boston, Massachusetts
- Conditions
- Leukemia
- Interventions
- gene expression analysis, molecular genetic technique, polymorphism analysis, protein expression analysis, diagnostic laboratory biomarker analysis
- Genetic · Other
- Lead sponsor
- Alliance for Clinical Trials in Oncology
- Other
- Eligibility
- 15 Years and older
- Enrollment
- 600 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2006
- U.S. locations
- 1
- States / cities
- Fort Wayne, Indiana
- Conditions
- Thrombocythemia, Essential, Primary Myelofibrosis
- Interventions
- Bomedemstat
- Drug
- Lead sponsor
- Imago BioSciences, Inc., a subsidiary of Merck & Co., Inc., (Rahway, New Jersey USA)
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 81 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 5
- States / cities
- Miami, Florida • Ann Arbor, Michigan • Cleveland, Ohio + 2 more
- Conditions
- Polycythemia Vera, Essential Thrombocytosis, Idiopathic Myelofibrosis, Neutrophils, Chronic Myeloproliferative Disorders
- Interventions
- Not listed
- Lead sponsor
- National Institutes of Health Clinical Center (CC)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 8 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2010
- U.S. locations
- 2
- States / cities
- Washington D.C., District of Columbia • Bethesda, Maryland
- Conditions
- Myelodysplastic Syndromes
- Interventions
- Sertraline, Bone Marrow Aspirate/Biopsy
- Drug · Procedure
- Lead sponsor
- Gustavo Rivero
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 14 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2020
- U.S. locations
- 2
- States / cities
- Houston, Texas
- Conditions
- Adult Myelodysplastic Syndrome, Anemia, Chronic Myelomonocytic Leukemia
- Interventions
- Eltrombopag Olamine, Laboratory Biomarker Analysis, Lenalidomide
- Drug · Other
- Lead sponsor
- Albert Einstein College of Medicine
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 52 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2020
- U.S. locations
- 2
- States / cities
- Kansas City, Kansas • The Bronx, New York
- Conditions
- Carcinoid Tumor, Acromegaly
- Interventions
- Pasireotide
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 85 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2013
- U.S. locations
- 4
- States / cities
- Los Angeles, California • Stanford, California • Tampa, Florida + 1 more
- Conditions
- Alcohol-Related Carcinoma, Fanconi Anemia, Oral Cavity Carcinoma
- Interventions
- Alcohol, Biospecimen Collection, Breath Test
- Drug · Procedure
- Lead sponsor
- Masonic Cancer Center, University of Minnesota
- Other
- Eligibility
- 18 Years to 45 Years
- Enrollment
- 170 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2027
- U.S. locations
- 1
- States / cities
- Minneapolis, Minnesota
- Conditions
- Multiple Myeloma
- Interventions
- Zoledronic acid
- Drug
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 29 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2012
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Essential Thrombocythemia
- Interventions
- Ropeginterferon alfa-2b, Anagrelide
- Biological · Drug
- Lead sponsor
- PharmaEssentia
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 174 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2029
- U.S. locations
- 4
- States / cities
- Scottsdale, Arizona • St Louis, Missouri • Houston, Texas + 1 more
- Conditions
- Myeloid Malignancy, Myelodysplastic Syndromes, Myelofibrosis, Acute Myeloid Leukemia, Myeloproliferative Neoplasm
- Interventions
- Navitoclax, Venetoclax, Decitabine
- Drug
- Lead sponsor
- Jacqueline Garcia, MD
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 16 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 3
- States / cities
- Boston, Massachusetts
- Conditions
- Chronic Lymphocytic Leukemia
- Interventions
- Venetoclax
- Drug
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 127 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2021
- U.S. locations
- 15
- States / cities
- La Jolla, California • Los Angeles, California • Stanford, California + 10 more
- Conditions
- Chronic Myeloproliferative Disorders, Infection, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes
- Interventions
- amphotericin B deoxycholate, nystatin
- Drug
- Lead sponsor
- Aronex Pharmaceuticals
- Industry
- Eligibility
- 2 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1996 – 2007
- U.S. locations
- 59
- States / cities
- Phoenix, Arizona • Fort Smith, Arkansas • Little Rock, Arkansas + 47 more
- Conditions
- Cancer, Chronic Myelomonocytic Leukemia
- Interventions
- Clofarabine
- Drug
- Lead sponsor
- University of Utah
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 11 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2014
- U.S. locations
- 1
- States / cities
- Salt Lake City, Utah